Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367574 · ClinicalTrials.gov registry record · Phase 2
Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01367574 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 39 participants.
The verdict
NCT01367574, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous methylnaltrexone to be conducted in patients with advanced medical illness and poorly controlled opioid induced constipation. Patients will be randomized to one of three fixed dose levels of SC MNTX.
Interventions
- DRUG SC MNTX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2002-04 |
| Est. Completion | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01367574
The ClinicalTrials.gov registry entry for NCT01367574 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SC MNTX is the first listed.
NCT01367574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01367574 about?
NCT01367574 is a clinical study titled "Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction". This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous methylnaltrexone to be conducted in patients with advanced medical illness and poorly controlled opioid induced constipation. Patients will be randomized to one of three fixed dose levels of SC MNTX.
What is the current status of trial NCT01367574?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2002-04. Estimated completion is 2003-05.
What interventions are being tested in trial NCT01367574?
The interventions under investigation include: SC MNTX (DRUG).
Who is sponsoring clinical trial NCT01367574?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.